Portal Range Monitoring in Mixed Ion Beam Surgery

PROMISE aims to revolutionize carbon ion radiotherapy by developing mixed ion beams for real-time tumor monitoring, enhancing treatment precision and potentially improving patient outcomes.

Subsidie
€ 2.000.000
2024

Projectdetails

Introduction

Half of the approximately 4 million annual cancer cases in Europe receive radiotherapy. While many cancer patients have benefitted from technical improvements in recent years, widespread diseases, such as pancreatic and lung cancer, still have dismally low cure rates, with median survival of less than 2 years.

Carbon Ion Radiotherapy (CIRT)

Carbon ion radiotherapy (CIRT) offers unprecedented precision in delivering tumour dose and can be the much-needed game changer for these patients. However, CIRT is vulnerable to uncertainties in patient positioning, anatomy changes, and organ motion.

Current Challenges

The current clinical approach is to increase the high dose volume to ensure target coverage, counteracting the primary advantage of CIRT. Novel strategies for image guidance and beam range assessment are crucial to unlock the full potential of CIRT for the best possible patient care.

PROMISE Project

PROMISE, for the first time, will produce mixed ion beams that enable concurrent treatment and image guidance.

How It Works

  1. Carbon ions deliver the dose to the target.
  2. Helium ions, simultaneously accelerated to the same velocity, traverse the patient and monitor tumour location and beam range.

PROMISE realizes true portal imaging, providing real-time information on the target anatomy as seen by the treatment beam. Coupled with innovative detectors, AI-based image recognition, and online dose reconstruction, this technique will enable a drastic reduction in safety margins and achieve the full potential of CIRT.

Development and Validation

The GSI accelerators are uniquely suited to develop the first mixed beam of Carbon and Helium, along with strategies for their cost-effective translation to existing and future clinical CIRT centres.

Experimental Validation

  • The method will be validated experimentally in GSI’s former CIRT treatment room.
  • Patient simulation studies will highlight clinical benefit and characterize ideal use cases.
  • A demonstration in an animal model will pave the way for clinical transition.

Conclusion

The mixed beam image guidance of PROMISE will lead to a paradigm shift in CIRT.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.000.000
Totale projectbegroting€ 2.000.000

Tijdlijn

Startdatum1-3-2024
Einddatum28-2-2029
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • GSI HELMHOLTZZENTRUM FUR SCHWERIONENFORSCHUNG GMBHpenvoerder

Land(en)

Germany

Vergelijkbare projecten binnen European Research Council

ERC Starting...

Prompt Gamma Time Imaging: a new medical-imaging modality for adaptive Particle Therapy

The project aims to enhance particle therapy efficacy and safety by developing Prompt Gamma Time Imaging for real-time monitoring of treatment, improving dose control and adaptive dosimetry.

€ 1.498.969
ERC Proof of...

Gamma-Neutron Vision aimed at improved cancer treatments in Hadron Therapy

This project aims to develop a portable device for simultaneous gamma-ray and thermal neutron imaging to enhance ion-range verification and secondary neutron dose assessment in proton therapy.

€ 150.000
ERC Starting...

Transformative Pediatric Brain Cancer Imaging using Integrated Biophysics-AI Molecular MRI

Develop a novel AI-driven molecular MRI technology for rapid, noninvasive monitoring of pediatric brain cancer treatment response, enhancing precision medicine and understanding of tumor dynamics.

€ 1.497.669
ERC Starting...

Nanoscintillators to potentiate brain cancer radiotherapy: from physics to preclinical trials

This project aims to enhance radiation therapy for glioblastoma by studying nanoscintillators' effects on tumor tissues, improving treatment efficacy while minimizing damage to healthy cells.

€ 1.948.125
ERC Proof of...

Hybrid Imaging in the Catheterization Room

This project aims to evaluate the IXSI c-arm scanner's potential in interventional cardiology to enhance treatment outcomes and develop a viable business case for its clinical application.

€ 150.000

Vergelijkbare projecten uit andere regelingen

Mkb-innovati...

Treatment planning assessment for the Optiflux radiosurgery system

Dit project ontwikkelt een innovatieve radiotherapie met sub-MeV X-stralen voor nauwkeurige tumorbehandeling en minder schade aan omliggende organen.

€ 20.000
EIC Transition

Radically New Cancer Therapy Based on Advances in Nanotechnology and Photonics for Simultaneous Imaging and Treatment of Solid Tumours

ScanNanoTreat aims to revolutionize cancer treatment by integrating advanced imaging and therapy technologies to improve patient outcomes and reduce costs, targeting clinical trials by 2027.

€ 2.499.911
EIC Pathfinder

Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis.

NuCapCure aims to develop novel cancer treatments for glioblastoma by utilizing custom-made drugs through biosynthesis to enhance proton and neutron therapies for better targeting and efficacy.

€ 5.972.875
EIC Transition

Very High Energy Electrons Beam for Radiotherapy

eBeam4Therapy aims to revolutionize cancer treatment by developing compact, cost-effective VHEE radiotherapy using laser plasma accelerators to improve patient outcomes and reduce side effects.

€ 2.477.043
EIC Pathfinder

NEXT GENERATION IMAGING FOR REAL-TIME DOSE VERIFICATION ENABLING ADAPTIVE PROTON THERAPY

The NOVO project aims to develop a groundbreaking real-time dose verification technology for proton radiotherapy, enhancing personalized cancer treatment and improving patient outcomes.

€ 3.759.489